PEPITA Study: An Observational Study of Tarceva (Erlotinib) in Second Line in Patients With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
This observational study will evaluate the efficacy and safety of Tarceva (erlotinib) in second line in patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after failure of first line platinum-based chemotherapy. Eligible patients will be followed for 12 months.
Non-Squamous Non-Small Cell Lung Cancer
Progression-free survival, 2 years
Clinical/demographic patients characteristics at baseline, 2 years|Treatment schedules: Dose/duration/modifications/interruptions, 2 years|Overall survival, 2 years|Safety: Incidence of adverse events, 2 years|Quality of life: FACT-L version 4 questionnaire, 2 years
This observational study will evaluate the efficacy and safety of Tarceva (erlotinib) in second line in patients with locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after failure of first line platinum-based chemotherapy. Eligible patients will be followed for 12 months.